Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

References

• Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Barnett AH Burger J Johns D Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial Clin Ther 2007 29 11 2333 2348 18158075
   PubMed Web of Science ®Google Scholar
• Heine RJ Van Gaal LF Johns D Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2005 143 8 559 569 16230722
   PubMed Web of Science ®Google Scholar
• Nauck MA Duran S Kim D A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Diabetologia 2007 50 2 259 267 17160407
   PubMed Web of Science ®Google Scholar
• Davies MJ Donnelly R Barnett AH Jones S Nicolay C Kilcoyne A Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study Diabetes Obes Metab 2009 11 1153 1162 19930005
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 2009 52 10 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE) Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87 London NICE 2009 Available from: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf. Accessed January 23, 2013.
   Google Scholar
• Bergenstal RM Garrison LPJr Wintle M Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting Curr Med Res Opin 2011 27 3 531 540 21219119
   PubMed Web of Science ®Google Scholar
• Fabunmi R Nielsen LL Quimbo R Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine Curr Med Res Opin 2009 25 3 777 786 19203299
   PubMed Web of Science ®Google Scholar
• Ryder RE Thong KY Cull ML Mills AP Walton C Winocour PH The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit Pract Diab Int 2010 27 8 352 357b
   Google Scholar
• Koro CE Bowlin SJ Bourgeois N Fedder DO Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report Diabetes Care 2004 27 1 17 20 14693960
   PubMed Web of Science ®Google Scholar
• Tzoulaki I Molokhia M Curcin V Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ 2009 339 b4731 19959591
   PubMed Web of Science ®Google Scholar
• Yurgin N Secnik K Lage MJ Obesity and the use of insulin: a study of patients with type 2 diabetes in the UK J Diabetes Complications 2008 22 4 235 240 18413211
   PubMed Web of Science ®Google Scholar
• Gedulin BR Nikoulina SE Smith PA Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 2005 146 4 2069 2076 15618356
   PubMed Web of Science ®Google Scholar
• Nielsen LL Young AA Parkes DG Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul Pept 2004 117 2 77 88 14700743
   PubMedGoogle Scholar
• Garber AJ Incretin effects on β-cell function, replication, and mass: the human perspective Diabetes Care 2011 34 Suppl 2 S258 S263 21525465
   PubMed Web of Science ®Google Scholar
• Li Y Hansotia T Yusta B Ris F Halban PA Drucker DJ Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J Biol Chem 2003 278 1 471 478 12409292
   PubMed Web of Science ®Google Scholar
• Xu G Stoffers DA Habener JF Bonner-Weir S Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 1999 48 12 2270 2276 10580413
   PubMed Web of Science ®Google Scholar
• Liu SC Tu YK Chien MN Chien KL Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis Diabetes Obes Metab 2012 14 9 810 820 22486990
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Byetta: exenatide; assessment history [web page on the Internet] London European Medicines Agency nd. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human_med_000682.jsp&jsenabled=true. Accessed December 10, 2012.
   Google Scholar
• Lilly Byetta^®approved for use with basal insulin in Europe [press release] San Diego, CA Amylin Pharmaceuticals 2012 [March 23]. Available from: https://investor.lilly.com/releasedetail2.cfm?ReleaseID=659089. Accessed December 10, 2012.
   Google Scholar
• Ligthelm RJ Borzì V Gumprecht J Kawamori R Wenying Y Valensi P Importance of observational studies in clinical practice Clin Ther 2007 29 Spec No: 1284 1292
   Web of Science ®Google Scholar
• Mann CJ Observational research methods. Research design II: cohort, cross sectional, and case-control studies Emerg Med J 2003 20 1 54 60 12533370
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy ClinicalTrialsgov [website on the Internet] Bethseda, MD US National Library of Medicine 2008 [updated April 12, 2010]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00635492. NLM identifier: NCT00635492. Accessed February 23, 2013.
   Google Scholar
• Matthaei S Reaney M Mathieu C Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study Diabetes Ther 2012 3 1 6 22714818
   PubMedGoogle Scholar
• Bergenstal RM Garrison LPJr Miller LA Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting Curr Med Res Opin 2011 27 12 2335 2342 22085180
   PubMed Web of Science ®Google Scholar
• Jones S Benroubi M Castell C Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study Curr Med Res Opin 2009 25 3 691 700 19196223
   PubMed Web of Science ®Google Scholar
• Yue LQ Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies J Biopharm Stat 2007 17 1 1 13 17219753
   PubMed Web of Science ®Google Scholar
• Simpson A Smith H Nicolay C Approaches to initiation of insulin therapy in patients with type 2 diabetes and resulting outcomes at 12 months in four European countries: data from the INSTIGATE study Poster presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) October 30–November 2, 2008 Barcelona, Spain
   Google Scholar
• Benroubi M Schmitt H Cleall SP the TREAT Study Investigators Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: results from the TREAT study Poster presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting September 12–16, 2011 Lisbon, Portugal
   Google Scholar
• Blak BT Smith HT Hards M Maguire A Gimeno V A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care Diabet Med 2012 29 8 e191 e198 22507537
   PubMed Web of Science ®Google Scholar
• Gordon J Pockett RD Tetlow AP McEwan P Home PD A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study Int J Clin Pract 2010 64 12 1609 1618 20946269
   PubMed Web of Science ®Google Scholar
• Hall GC McMahon AD Dain MP Home PD A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes Diabetes Res Clin Pract 2011 94 3 442 448 21963105
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Buysschaert M Preumont V Oriot PR UCL Study Group for Exenatide One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice Diabetes Metab 2010 36 5 381 388 20598606
   PubMed Web of Science ®Google Scholar
• Bunck MC Diamant M Cornér A One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 2009 32 5 762 768 19196887
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Crasto W Jarvis J Khunti K Davies MJ New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes Postgrad Med J 2009 85 1003 257 267 19520878
   PubMed Web of Science ®Google Scholar
• Vaag A Lund SS Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues Eur J Endocrinol 2012 166 2 159 170 21930715
   PubMed Web of Science ®Google Scholar
• Waugh N Cummins E Royle P Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation Health Technol Assess 2010 14 36 1 248
   Web of Science ®Google Scholar
• Zinman B Schmidt WE Moses A Lund N Gough S Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme Diabetes Obes Metab 2012 14 1 77 82 21883806
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes-2012 Diabetes Care 2012 35 Suppl 1 S11 S63 22187469
   PubMed Web of Science ®Google Scholar
• Ryder RE Thong K ABCD nationwide exenatide and liraglutide audit contributors ABCD nationwide exenatide and liraglutide audits Presented at Diabetes UK Annual Professional Conference March 30–April 1, 2011 London, UK
   Google Scholar